Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:1814-21.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Trial profile Fox K et al. Lancet 2008;372:

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Shalev V, et al. Arch Intern Med 2009; 169:

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Flow diagram of the systematic literature search indicating the inclusion and exclusion process of studies Liakopoulos OJ, et al. Eur Heart J 2008;29:

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic Value of Cardiac Computed Tomography.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

The SPRINT Research Group

Copyright © 2006 American Medical Association. All rights reserved.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Figure 1 Ischaemic endpoints

LEADER trial: Primary Outcome

Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Valsartan in Acute Myocardial Infarction Trial Investigators

Ahead of the Curve by Alun D. Hughes Hypertension Volume 64(5):

Prognostic Value of Coronary Artery Calcium Score in Acute Chest Pain Patients Without Known Coronary Artery Disease: Systematic Review and Meta-analysis

Systolic Blood Pressure Intervention Trial (SPRINT)

on behalf of the LEADER Trial Steering Committee and Investigators

Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis S Hajibandeh, S Hajibandeh,

Baseline characteristics of patients

Robert W. Yeh et al. JACC 2017;70:

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p for noninferiority < 0.001)

Potential mechanisms whereby statins may reduce the risk of stroke

Characteristics of elderly patients prescribed statins after acute myocardial infarction (AMI) in Quebec, Ontario and British Columbia - Part I Zheng.

Svend A. Mortensen et al. JCHF 2014;2:

Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

Flow Diagram of the Trial Selection Process

Rahilly-Tierney CR et al. Circulation 2009;120:1491-7

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Baseline Characteristics of the Patients – Part I

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Baseline characteristics of study population

Flowchart of the process of study selection LAR indicates laboratory-defined aspirin resistance Jaapjan D. Snoep, et al. Arch Intern Med 2007;167:

Increase of physical activity over time associated with lower HF risk

Right internal thoracic artery versus radial artery as the second best arterial conduit: Insights from a meta-analysis of propensity-matched data on long-term.

Presentation transcript:

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:1814-21

Characteristics of 13 Trials Meeting Criteria for Inclusion in the Meta-analysis Hulten E, et al. Arch Intern Med 2006;166:1814-21

Forest plot of any cardiovascular event by duration of treatment HR indicates hazard ratio; CI, confidence interval Hulten E, et al. Arch Intern Med 2006;166:1814-21

Pooled Hazard Ratios (HRs) for Any Cardiovascular Event Over 24 Months Hulten E, et al. Arch Intern Med 2006;166:1814-21

Pooled survival curves by outcome Any cardiovascular event (A); myocardial infarction (B); ischemia (unstable angina or revascularization) (C); cardiovascular death (D) Hulten E, et al. Arch Intern Med 2006;166:1814-21

Pooled Hazard Ratios (HRs) for Subgroups Over 24 Months Hulten E, et al. Arch Intern Med 2006;166:1814-21

Adverse Events Among Intensive Statin and Control Groups Hulten E, et al. Arch Intern Med 2006;166:1814-21

References Hulten E, et al. Arch Intern Med 2006;166:1814-21